Skip to main content
Clinical Trials/NCT04932200
NCT04932200
Unknown
Not Applicable

A Prospective Multicenter Cohort Study on the Timing of Emergency Endoscopy for Esophagogastric Variceal Bleeding in Cirrhosis

Renmin Hospital of Wuhan University1 site in 1 country608 target enrollmentJune 15, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Liver Cirrhosis
Sponsor
Renmin Hospital of Wuhan University
Enrollment
608
Locations
1
Primary Endpoint
six-week mortality rate
Last Updated
4 years ago

Overview

Brief Summary

This study is a prospective, multi-center and observational clinical study. Investigators would like to explore the optimal emergency endoscopy timing in cirrhosis patients with esophagogastric variceal bleeding (EGVB) by evaluating and comparing the efficacy and safety of emergency endoscopy performed at different times ( within 6 hours or between 6 and 24 hours after gastroenterologic consultation ) and its impact on the short-term prognosis.

Detailed Description

Between July 2021 and April 2022, patients with cirrhosis undergoing emergency endoscopy due to EGVB are enrolled consecutively according to the following criteria: (1) age≥18 years; (2) A definite diagnosis of cirrhosis (confirmed by medical history, laboratory examination and imaging examination); (3) The cause of bleeding was identified as esophageal and/or gastric vein rupture. Exclusion criteria are as follows: (1) End-stage diseases of major organs (such as heart failure, chronic obstructive pulmonary disease, end-stage renal disease, and malignancies other than hepatocellular carcinoma); (2) The subject (or legal representative/guardian) refused to sign the informed consent. Patients were divided into urgent-endoscopy group (\< 6h) and early-endoscopy group (6h-24h) according to the time interval from gastroenterologic consultation to the start of emergency endoscopy. Investigators will collect patients' data of baseline character, treatment, postoperative and follow-up. All patients will be followed up until death or the end of the study.

Registry
clinicaltrials.gov
Start Date
June 15, 2021
End Date
April 30, 2022
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

ChenMingkai

Professor

Renmin Hospital of Wuhan University

Eligibility Criteria

Inclusion Criteria

  • age≥18 years
  • A definite diagnosis of cirrhosis (confirmed by medical history, laboratory examination and imaging examination)
  • The cause of bleeding was identified as esophageal and/or gastric vein rupture

Exclusion Criteria

  • End-stage diseases of major organs (such as heart failure, chronic obstructive pulmonary disease, end-stage renal disease, and malignancies other than hepatocellular carcinoma)
  • The subject (or legal representative/guardian) refused to sign the informed consent

Outcomes

Primary Outcomes

six-week mortality rate

Time Frame: 6 weeks after treatment

Patients died in six weeks after emergency endoscopy due to rebleeding or other complications associated with cirrhosis.

Secondary Outcomes

  • mean operating time(during endoscopy)
  • Immediate success hemostasis rate(within 24 hours after traetment)
  • the needs of salvage treatment(6 weeks)
  • detection rate of bleeding site(during endoscopy)
  • five-day rebleeding rate(5 days after treatment)

Study Sites (1)

Loading locations...

Similar Trials